1. Home
  2. SHMD vs FHTX Comparison

SHMD vs FHTX Comparison

Compare SHMD & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SCHMID Group N.V. Class A Ordinary Shares

SHMD

SCHMID Group N.V. Class A Ordinary Shares

BUY

Current Price

$6.32

Market Cap

323.0M

Sector

N/A

ML Signal

BUY

Logo Foghorn Therapeutics Inc.

FHTX

Foghorn Therapeutics Inc.

HOLD

Current Price

$4.90

Market Cap

332.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SHMD
FHTX
Founded
1864
2015
Country
Germany
United States
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
323.0M
332.2M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
SHMD
FHTX
Price
$6.32
$4.90
Analyst Decision
Strong Buy
Analyst Count
0
8
Target Price
N/A
$11.50
AVG Volume (30 Days)
780.1K
126.7K
Earning Date
01-01-0001
06-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
25.32
EPS
N/A
N/A
Revenue
N/A
$30,909,000.00
Revenue This Year
N/A
$14.62
Revenue Next Year
N/A
$15.27
P/E Ratio
N/A
N/A
Revenue Growth
N/A
36.75
52 Week Low
$2.00
$2.94
52 Week High
$10.65
$6.95

Technical Indicators

Market Signals
Indicator
SHMD
FHTX
Relative Strength Index (RSI) 43.32 35.07
Support Level $2.38 $4.44
Resistance Level $6.70 $5.85
Average True Range (ATR) 0.98 0.37
MACD -0.05 -0.09
Stochastic Oscillator 14.78 15.75

Price Performance

Historical Comparison
SHMD
FHTX

About SHMD SCHMID Group N.V. Class A Ordinary Shares

Schmid Group NV is a global supplier of equipment, software and services for various industries such as printed circuit board (PCB), substrate manufacturing, photovoltaics, and glass and energy storage with a focus on the highest end of this market in terms of technology and performance. It focuses on a modular product portfolio of machinery to use in the manufacturing of high-end PCB equipment and semiconductor packaging devices which includes common flexible circuit fabrication techniques such as subtractive, semi-additive processes (SAP) and modified semi-additive processes (mSAP).

About FHTX Foghorn Therapeutics Inc.

Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.

Share on Social Networks: